RJFSA
XENE icon

Raymond James Financial Services Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,250
Closed -$158K – 3276
2020
Q4 		$158K Buy
+10,250
New +$120K ﹤0.01% 2782

Other funds holding XENE

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raymond James Financial Services Advisors's XENE Position: Q1 2021 in Review

Raymond James Financial Services Advisors sold out of Xenon Pharmaceuticals (XENE) in Q1 2021, closing a stake of 10,250 shares — an estimated $158K sold.

Raymond James Financial Services Advisors first reported a position in XENE in Q4 2020 and held it in 1 quarter. The position peaked at $158K in Q4 2020. 91 funds tracked by Wall St. Rank hold XENE as of Q1 2021.

  • Raymond James Financial Services Advisors reported no remaining Xenon Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,250 Xenon Pharmaceuticals shares in Q1 2021, an estimated $158K.
  • Raymond James Financial Services Advisors first reported a position in Xenon Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Xenon Pharmaceuticals position peaked at $158K in Q4 2020.
  • 91 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2021, filed 14 May 2021.